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Proximal Crohn’s disease, involving the esophagus, the stomach, the duodenum, and the proximal jejunum, is uncommon.
Treatment for proximal Crohn’s disease is based on data derived from case series than from controlled trials. We present a
case of Crohn’s colitis with concomitant proximal esophagogastroduodenal involvement treated with conventional treatment plus
swallowed aerosolized budesonide as a novel adjuvant topical treatment for the esophageal disease, and we review the treatment
options for proximal Crohn’s disease.
1.Introduction
Crohn’s disease (CD) is a chronic inﬂammatory disease of
unknown etiology characterized by a chronic, granuloma-
tous,segmentaltransmuralinﬂammationthatmayaﬀectany
part of the gastrointestinal (GI) tract. The ileum, the colon,
the rectum, and the perianal region are the most frequent
locations of disease involvement. Proximal Crohn’s disease,
involving the esophagus, the stomach, the duodenum and
the proximal jejunum, is uncommon with a prevalence
of 0.5% to 13% in patients with ileocolonic CD [1, 2],
while isolated esophageal CD has been rarely described [3].
Although upper GI CD is uncommon in adults, it is seen
frequently in children [3]. Patients with proximal CD usually
presentwithconcomitantsmallorlargeboweldisease.Today,
the incidence of proximal disease is increased since CD
patients more frequently undergo upper GI endoscopy. The
recent European consensus (European Crohn’s and Colitis
Organization (ECCO)) on diagnosis and management of
Crohn’s disease propose treatments for esophageal and
gastroduodenal disease based on data derived from case
series than from controlled trials [4]. In this paper we
present a case of Crohn’s colitis with concomitant proximal
esophago-gastroduodenal involvement that was treated with
conventional treatment according to ECCO guidelines plus
swallowedaerosolizedbudesonideasanoveladjuvanttopical
treatment for esophageal disease.
2. Case Presentation
A 21-year-old male presented with abdominal pain, watery
diarrhea, low-grade fever and a 5kg weight loss during
the last 3 weeks. The patient was lean (Body Mass Index:
16.8Kg/cm), did not smoke or drink alcohol. His past
history was unremarkable and did not take any medica-
tion. Physical examination revealed mild diﬀuse abdominal
tenderness. Laboratory studies revealed elevated ESR, CRP,
platelet count, and the presence of leukocytes in the stool
without blood, parasites, or ova. Chest X-ray was nor-
mal, and Mantoux test was negative. Colonoscopy showed
longitudinal ulcers from sigmoid colon through cecum2 Case Reports in Medicine
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Figure 1: Colonoscopy demonstrated active colitis with longitu-
dinal ulcers from sigmoid colon through cecum (a) and a normal
terminal ileum (b).
(Figure 1(a)) and a normal terminal ileum (Figure 1(b)).
Histological examination demonstrated features of active
Crohn’s colitis without ileitis. Small bowel follow-through
series were normal. Treatment with oral mesalazine (3g/day)
and metronidazole (500mg twice daily for 10 days) was
started.
The patient had no symptoms of proximal disease, but
it is the standard practice in our department to perform
supplementary upper GI endoscopy in all patients with ileal
and/orcolonicCDinordertodeﬁnethesites,theextent,and
the phenotype of the disease according to Montreal classiﬁ-
cation [4]. Gastroscopy revealed multiple punch-out ulcers
in the esophagus (Figure 2(a)) and erosions in the stomach
(Figure 2(b)) and the duodenum (Figure 2(c)). Although
histology showed nonspeciﬁc mild inﬂammatory reaction
withoutevidenceofcytomegalovirus(CMV),herpessimplex
virus (HSV), or Candida albicans infection, the endoscopic
appearance, the location and extent of the lesions combined
with the active Crohn’s colitis and the negative history of
NSAIDs use, were suggestive for proximal CD.
Getting the idea from eosinophilic esophagitis’ treatment
[5, 6], “topical” treatment with ingestion of inhalable
budesonide (Pulmicortturbuhaler;AstraZeneca LP,Sweden)
together with oral pantopazole were added for the man-
agement of the esophageal and the gastroduodenal disease.
The symptoms of colitis subsided completely after 2 weeks
and in the 3rd month of followup the patient reported
a 10-kg weight gain. A followup upper GI endoscopy
showed disappearance of the esophageal disease (Figure 3)
with persistence of gastric and duodenal erosions. Since
the patient was asymptomatic from the proximal and distal
disease he was set in a regular followup schedule with the
(a)
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Figure 2: Upper gastrointestinal endoscopy revealed proximal
Crohn’s disease with erosions in esophagus (a), stomach (b) and
duodenum (c).
Figure 3: Follow-up with upper gastrointestinal endoscopy show-
ing complete healing of the esophageal erosions after 3 months of
topical treatment with swallowed budesonide.
same treatment (5-ASA, (PPIs) and inhalable budesonide)
and the recommendation to avoid the use of NSAIDs.
Unfortunately, a few months later the patient experi-
enced a new ﬂare of the distal disease, which was man-
aged successfully with systemic corticosteroids, starting with
32mg oral methyl-prednisolone and following a 12-week
tapering scale after remission of symptoms was noted.
Subsequently, azathioprine (2mg/kg/day) was added to the
treatment as a steroid-sparing agent to maintain remission.
Complete and sustained disease remission, clinical andCase Reports in Medicine 3
endoscopic, was achieved throughout the gastrointestinal
tract as evidenced during followup visits.
3. Discussion
Usually the proximal involvement is diagnosed when a CD
patient with known small and/or large bowel disease under-
goes endoscopy for complaints or symptoms mimicking
upper GI diseases, including gastroesophageal reﬂux disease,
dyspepsia, and peptic ulcer disease. Sometimes the proximal
involvementissilentandthediseaseisdiagnosedincidentally
during endoscopy in an asymptomatic patient [1, 3].
Upper GI endoscopy with multiple mucosal biopsies will
establish the diagnosis of proximal Crohn’s disease in most
of the cases. In the majority of cases the proximal disease
extends beyond the esophagus, involving the stomach and
the duodenum too. The most common endoscopic features
in esophageal Crohn’s disease include single or multiple
erosions, aphthous ulcers or deep punched-out ulcers, with
either local or extensive involvement surrounded by normal-
looking mucosa. The antrum and the duodenum are most
frequently involved than the proximal stomach is. Granular
mucosa, patchy erythema, superﬁcial or deep ulcerations
can be observed [1]. Stenosis is the major complication of
proximal CD while ﬁstulas are infrequent [1].
The lesions in the proximal involvement must be
diﬀerentiated from diseases aﬀecting the organ involved.
Lesions in the esophagus must be diﬀerentiated from reﬂux
esophagitis and infectious esophagitis (CMV, HSV, Candida
albicans). Helicobacter pylori gastritis and granulomatous
gastritis(Wegener’sgranulomatosisornecrotizingvasculitis)
must be excluded in the stomach. Giardiasis, coeliac disease,
lymphoma must be considered in the diagnosis when
duodenum is involved. Of course when features of CD are
present in the distal GI tract the diagnosis is more secure [1].
Treatment of proximal CD depends on the severity of
the disease. The ECCO consensus underscores the lack con-
trolled studies to demonstrate the eﬀectiveness of drug ther-
apy and proposes the addition of a proton pump inhibitor
in the conventional treatment for distal disease or the use
of systemtic corticosteroids and thiopurines or methotrexate
[4]. The administration of 5-aminosalicylates (5-ASA) is a
logical treatment, but their eﬀect is not certain since these
products are not activated in the proximal gastrointestinal
tract. Antisecretory drugs (histamine receptor antagonists;
HRAs and proton-pump inhibitors; PPIs) may relieve pain,
but their eﬃcacy in mucosal healing has not been proven
[1]. On the other hand, some authors raised the concern
that omeprazole monotherapy could lead to stricturing
and ﬁstulization because of continued inﬂammation [3, 7].
Corticosteroids as a systemic therapy are the best treatment
of choice, while no data exist on the therapeutic eﬀect of
budesonide formulations [1]. Immunosuppressive therapy
with azathioprine, 6-mercaptopurine or methotrexate is an
excellent steroid-sparing option for long-term maintenance
which is also indicated for the management of the concomi-
tant distal disease [2, 4]. Anti-TNF therapy is an alternative
treatment for severe or refractory disease as recommended
by ECCO consensus which suggested that clinicians should
have a lower threshold for starting anti-TNF therapy than
for disease elsewhere, given the poor prognosis of Crohn’s
disease with proximal involvement [4, 8, 9].
There is no recommendation for topical treatment of
proximal CD with steroids or 5-ASA, although Rholl et al.
reported the successful management of esophageal Crohn’s
disease complicated with an esophagogastric ﬁstula with
topical administration of 5-ASA and steroids in liquid form
[10].
In our case we used aerosolized budesonide indicated for
asthma, instructing the patient not to inhale but to swallow
the drug as has been suggested in eosinophilic esophagitis
treatment [5, 6]. With this application we consider that
as u ﬃcient amount of budesonide will reach the entire
esophagus, achieving in that way a “topical” treatment.
Indeed, in a followup endoscopy the esophageal lesions were
healed, but the more distal disease was still active. Finally, the
addition of azathioprine induced and maintained remission
was curative for all locations of disease.
4. Conclusion
We believe that routine upper GI endoscopy in patients
with CD, even when topical symptoms are lacking, helps to
diagnose proximal involvement which must be diﬀerentiated
from other ulcerative conditions [11, 12]. The optimal
treatment for esophageal CD has not been established but
topical corticosteroids oﬀer an eﬀective adjuvant therapeutic
option together with those classically suggested for proximal
disease [2].
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